Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematologic cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting CD205. The study included preclinical in vitro a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaudio, Eugenio, Tarantelli, Chiara, Spriano, Filippo, Guidetti, Francesca, Sartori, Giulio, Bordone, Roberta, Arribas, Alberto J., Cascione, Luciano, Bigioni, Mario, Merlino, Giuseppe, Fiascarelli, Alessio, Bressan, Alessandro, Mensah, Afua Adjeiwaa, Golino, Gaetanina, Lucchini, Renzo, Bernasconi, Elena, Rossi, Davide, Zucca, Emanuele, Stussi, Georg, Stathis, Anastasios, Boyd, Robert S., Dusek, Rachel L., Bisht, Arnima, Attanasio, Nickolas, Rohlff, Christian, Pellacani, Andrea, Binaschi, Monica, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604571/
https://www.ncbi.nlm.nih.gov/pubmed/33131247
http://dx.doi.org/10.3324/haematol.2019.227215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604571/
https://www.ncbi.nlm.nih.gov/pubmed/33131247
http://dx.doi.org/10.3324/haematol.2019.227215

Ejemplares similares